safety of erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study [published online January 1, 2018]. Cephalalgia. doi: 10.1177/0333102418788347.
home / authors / safety-of-erenumab-amg334-in-chronic-migraine-patients-with-prior-preventive-treatment-failure-a-subgroup-analysis-of-a-randomized-double-blind-placebo-controlled-study-published-online-january-1-2018-cephalalgia-doi-101177-0333102418788347